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Abstract 
In the last decade, Malaysia has experienced several hand, foot and mouth disease (HFMD) epidemics, 
complicated by fatalities due to severe neurological involvement. Enterovirus 71 (EV-71) has been 
implicated as the major causative agent for these epidemics. EV-71 infection is a global public health 
problem with pandemic potential. In many parts of Asia-Pacifi c, the virus has emerged as one of the 
most deadly virus infections amongst young children. The virus is highly transmissible through faecal-
oral route and respiratory droplets. A recent rise in neurological complications and deaths suggests 
that the viruses currently circulating may be more virulent. The major risk factor associated with 
more severe EV-71 infection is young age and poor cellular immunity. Rapid laboratory diagnosis and 
molecular surveillance is important to closely monitor the emergence of new EV-71 subgenotypes. 
Since vaccine and anti-virals for EV-71 are not available, control and prevention strategies remain 
the only ways to combat the infection.
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INTRODUCTION
Since its fi rst isolation in California in 1969, 
enterovirus 71 (EV-71) has caused sporadic 
outbreaks of hand, foot and mouth disease 
(HFMD), as well as serious neurological diseases 
such as meningitis, encephalitis, and acute 
fl accid paralysis (AFP). In the last 15 years, 
these epidemics have increased in number and 
involved large numbers of children in Asia, 
including Malaysia. 
 In this review, we will discuss the epidemiology, 
clinical manifestations, risk factors, diagnosis, and 
management of EV-71 infection, with particular 
reference to work in Malaysia, and our diagnostic 
virology laboratory in University Malaya Medical 
Centre (UMMC), in Kuala Lumpur, Malaysia. 
VIROLOGY OF EV-71
EV-71 belongs to the Picornaviridae family. 
Picornaviruses are small, about 28 nm in size, 
non-enveloped, and consist of icosahedral 
particles with a positive-stranded RNA genome. 
Based on nucleotide sequences, physico-
chemical properties, serological relatedness and 
pathogenicity in man or mice, EV-71 is classifi ed 
in the genus enterovirus along with polioviruses, 
coxsackievirus A (CV-A) and coxsackievirus 
B (CV-B), echoviruses, EV-70, and bovine 
enteroviruses.1-2 EV-71 belongs to the species 
Human enterovirus A (HEV-A), which also 
includes other important human pathogens such as 
coxsackieviruses A2-A8, A10, A14, and A16.3-4 
 The EV-71 genome encodes a long polyprotein 
with a single open reading frame followed by a 
poly A tract. The single polyprotein is fl anked by 
untranslated regions at both the 5’ and 3’ ends, 
and are cleaved into different structural (VP1-
VP4) proteins, which form the physical structure 
of the virus, and non-structural proteins (2A-2C, 
3A-3D), which include enzymes important for 
host interaction and replication (Figure 1). 
GLOBAL EPIDEMIOLOGY OF 
ENTEROVIRUS 71
Global prevalence of EV-71
After the fi rst outbreak in California in 1969, 
EV-71 was subsequently associated with several 
other outbreaks, in Bulgaria5, Japan6, Hungary7, 
Australia8-9, China10, Malaysia11, Taiwan12-13, Hong 
Kong14, Korea15-16, Vietnam17, Macao18, Brunei19, 
and, more recently, China20 and Singapore in 2008. 
European countries such as Germany21, Norway22, 
United Kingdom23, Austria24, Netherlands25, 
France26 and Hungary27 have also reported EV-71 
cases. EV-71 infection is therefore a global health 
problem with pandemic potential.  
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Global increase of EV-71 activity
There has been increased EV-71 activity in the 
Asia Pacifi c region since 1997.28 We compared 
surveillance data from USA, Japan, Singapore and 
Taiwan. In the USA, more than 50% of the 1,520 
HEV-A reported were CV-A16 (40.5%) and EV-71 
(17.8%).29 In the 1970s and 1980s, CV-A16 was 
most frequently isolated, but was then replaced 
by EV-71 after the 1990s.29 In Japan, enterovirus 
surveillance from 1982-2010 showed that of the 
28,882 HEV-A isolates, 24.4% were CV-A16 and 
17.5% were EV-71.30 Of 4,181 HEV-A isolates 
reported in Taiwan between 1998-2005, the most 
common enteroviruses were EV-71 (40.9%) and 
CV-A16 (40.7%).31 Surveillance from Singapore 
from 2001-2007 also revealed similar trends, with 
CV-A16 (40.8%) and EV-71 (31.4%) as the main 
enteroviruses.32 
ENTEROVIRUS 71 IN MALAYSIA
Outbreaks of fatal hand, foot and mouth disease 
in Malaysia 
In mid-1997, an outbreak of acute viral infection 
in Sarawak, Malaysia caused 31 deaths among 
young children aged between fi ve months to 
six years.11, 33 In most cases, the children died 
within hours of admission to hospitals due to 
acute congestive heart failure and cardiovascular 
collapse, which was suggestive of acute viral 
myocarditis. Occurrence of the fatal infections 
in the midst of simultaneous outbreaks of EV71-
associated HFMD raised the possibility that 
EV71, or another enterovirus, was associated 
with the deaths. Based on the clinical presentation 
resembling myocarditis, group B coxsackieviruses 
Figure 1. EV-71 genome organization.  The genome organization and function of the EV-71 genes is similar to 
other enteroviruses.4  
(CV-B) were initially thought to be the causative 
agent. However, CV-B was not detected in these 
fatal cases.  Instead, a novel adenovirus was 
isolated from some of the fatal cases, in addition 
to EV-71.34-35 A few months following the outbreak 
in Sarawak, fatal brainstem encephalomyelitis 
was reported in at least four young children in 
Peninsular Malaysia.36 In all cases, EV-71 was 
isolated and identifi ed from central nervous system 
tissue samples.11  
 In 2000, another fatal HFMD outbreak hit 
Malaysia. In addition to EV-71, echovirus 7 was 
also identifi ed as a possible causative agent for 
three cases of acute encephalomyelitis.37 Large 
outbreaks with fatalities continued to be seen in 
3-yearly cycles in Sarawak in 2003, 200638 and 
2008/2009.39 
EV-71 in Malaysia before 1997
No data is available on EV-71 or HFMD prior to 
1997. Laboratory records at UMMC showed that 
samples were received from patients with HFMD 
between 1982 to 1997, but no virus isolates are 
available. A seroprevalence study on archived 
sera will help to show if EV-71 was present in 
Malaysia before 1997. 
EV-71 in Malaysia after 1997
After the 1997 EV-71 fatal outbreak in Malaysia, 
our laboratory began confi rmation of EV-71. 
From 1997 to 2008, 1,098 samples from patients 
suspected with enterovirus infection were 
received in the virology laboratory in UMMC, 
and of these, 202 (18.6%) samples were culture-
confi rmed positive for EV-71, particularly during 
the outbreak years of 1997, 2000, and 2006. No 
3EV-71 was isolated in 2002 and 2004. From 2000 
onwards, the laboratory also began confi rmation 
of CV-A16 and since then, CV-A16 has been 
identifi ed in 48 patients. Of these, 33.3% (16/48) 
and 37.5% (18/48) were reported in 2000 and 
2002, respectively, while no CV-A16 was isolated 
in 2001 and 2003. The number of patients with 
confirmed CV-A16 infection was relatively 
small which suggests that it is uncommon for 
CV-A16 to cause more severe forms of HFMD 
that warrant hospitalization, at least in UMMC. 
In Sarawak, EV-71 was seen during the outbreak 
years, while CV-A16 was seen in both outbreak 
and inter-outbreak periods.40
 The average incidence rate (per 100,000 
population) for 2000-2008 was 25.0 (range, 1.5-
60.6). Data from Ministry of Health Malaysia 
(MOH)41 showed that the incidence rate of 
HFMD was as high as 56.1 and 60.6 in 2007 
and 2008, respectively. This may be because 
HFMD was declared a notifi able disease in 2006. 
Nevertheless, it is highly likely that the disease 
remains underreported. The average mortality rate 
(per 100,000 population) for 2000-2009 was 0.01 
(range 0-0.3). No deaths were reported in 2002, 
2004, 2007 and 2009. 
EV-71 genotype distribution 
Generally, EV-71 is divided into four broad 
genotypes: A, B, C and D (previously designated 
as C4), based on analysis of complete genome 
sequences of many strains.42 Genotyping and 
phylogenetic analysis provides useful information 
on the evolution and epidemiology of EV-71, 
such as confi rming outbreaks and demonstrating 
geographical spread. Genotype A contains the 
prototype virus BrCr. Genotype B is further 
divided into B1-B4 (B4 was recently proposed to 
be merged with B5 based on its complete genome 
relatedness) while genotype C is further divided 
into C1-C3 and C5 (Figure 2).  
 Van Sanden et al. (2009)25 reported the earliest 
EV-71 isolate, from 1963. Recent bioinformatics 
analysis showed that EV-71 probably evolved 
as early as 1942.43 Based on molecular 
epidemiological studies performed using publicly 
available EV-71 VP1 or VP4 gene sequences, 
the distribution of different EV-71 in different 
parts of the world was mapped (Figure 3). Our 
review of the published literature shows that only 
several EV71 subgenotypes - B4 (previously B5), 
C1, C2, C5 and D are currently circulating in the 
world.  While all these genotypes are found in 
Asia, only genotype D, subgenotype C1 and C2 
are circulating in Europe (Figure 3). Subgenotype 
B1 was last seen in 1986, subgenotype B2 in 
1994, while subgenotypes B3 and C3 only 
circulated briefl y during 1997-1998 and 1997-
2000, respectively. Of note, genotype A has been 
reported to have reemerged in China during the 
HFMD outbreaks in 2008 and 2009; however these 
isolates may not have evolved together with other 
subgenotypes because of its high similarity with 
the prototype BrCr.44 In Malaysia, subgenotypes 
C1, C2, B3 and B4 have been reported, but 
recently, predominantly, subgenotype B4 (B5) 
is circulating in both Peninsular Malaysia and 
Sarawak.
Seasonal distribution and cyclical EV71 
outbreaks?
Seasonal distribution has been observed for 
enteroviruses in temperate countries between June 
to October, the summer and early fall months.4 
HFMD surveillance in Singapore from 2002-
2009 showed that annual peaks occurred between 
March to May.45 Similarly, sentinel surveillance 
for enteroviruses from 1998-2005 in Sarawak 
also showed the occurrence of HFMD around 
March to June.40 An 8-year epidemiologic study 
in Taiwan (1998-2005) showed that more severe 
HFMD occurred around April-June.31 Limited 
surveillance data is available for Peninsular 
Malaysia. Based on the small number of 202 
laboratory confi rmed cases seen in UMMC in 
Kuala Lumpur, EV-71 was most frequently 
isolated between June to October. This hospital 
data refl ects more severe cases and increased 
reporting due to public awareness in seeking 
treatment, in contrast to the active surveillance 
of HFMD cases from sentinel clinics in Sarawak 
and Singapore.     
  Some sites have reported cyclical patterns 
of EV-71 outbreaks, which we did not see with 
our limited hospital cases in Kuala Lumpur. In 
Sarawak, EV-71 HFMD outbreaks occurred in a 
cyclical pattern of approximately every two to 
three years.40 The Infectious Disease Surveillance 
Center in Japan showed a similar cyclical trend, 
with predominantly EV-71 isolation in 1983, 
1986, 1990, 1993, 1997, 2000, 2003, 2006 and 
2010.30  
TRANSMISSION OF EV-71
Humans are the only known reservoir for EV-71. 
The faecal-oral route is the commonest mode of 
transmission, although respiratory droplet spread 
may also play a role.4 EV-71 shedding in the 
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stool was longer than in the throat46, and may 
be for up to 42 days post-infection.47 During the 
EV-71 outbreak in Taiwan in 2001-2002, the 
principal transmission was between children in 
childcare facilities. However, the transmission 
rate to household contacts was as high as 52%, 
especially to siblings and cousins.48 Adults are 
rarely infected, as most adults already have 
previous immunity. However, infected adults may 
excrete the virus without signs and symptoms, and 
transmit virus to susceptible children.  
 EV-71 has been isolated from worldwide 
HFMD outbreaks every year, suggesting the 
continuous circulation of the virus in the 
population. The persistence of enteroviruses has 
been well documented in the environment, such 
as in sewage and water systems4, and in spring 
water and environmental water in Taiwan.49-50 
EV-71 may also survive in the environment for 
at least three days at tropical room temperature.51 
The persistence of EV-71 in the environment 
may provide a continuing source of potential 
exposure for susceptible populations. A very 
low rate of enterovirus infections amongst blood 
donors has been documented, suggesting that 
blood components are unlikely to be an important 
route of transmission.52 Perinatal transmission of 
enterovirus infections are common, however in 
EV-71 only one case has been documented.4,53
 
CLINICAL MANIFESTATIONS OF EV-71 
INFECTION 
Clinical manifestations of EV-71 range from 
asymptomatic to involvement of upper respiratory 
tract, gastrointestinal tract, central nervous system 
and cardiovascular system. Up to 71% of EV-71 
infections in children may be asymptomatic, and 
may serve as a reservoir for transmission.54 EV-71 
is associated with HFMD, meningoencephalitis, 
poliomyelitis-like paralysis and aseptic meningitis 
(non-paralytic poliomyelitis). Chang et al. 
(2004)55 classifi ed symptomatic EV-71 infection 
into four stages.
Hand, foot and mouth disease and herpangina
Uncomplicated disease, or stage 1, mainly 
manifests as HFMD or herpangina. The most 
common causes of HFMD are CV-A16 and EV-
71. Other enteroviruses associated with HFMD 
include CV-A4, A5, A10, B2 and B5.  The 
incubation period for HFMD ranges from 3 to 
7 days. The infectious period starts from several 
days before the appearance of symptoms and peaks 
within one week of disease onset. The common 
signs and symptoms are fever, sore throat, and 
exanthema. Vesicular or maculopapular rash can 
appear on palms, feet and buttocks (Figure 4). 
Vesicles and ulcers can also be found in the oral 
cavity especially on the tongue and soft palate 
(Figure 4). In herpangina, only oropharyngeal 
lesions occur. Most cases are mild, self-limiting 
and do not warrant any hospitalization. 
Central nervous system involvement
The enteroviruses associated with central 
nervous system (CNS) infection are echoviruses, 
polioviruses and EV-71. In stage 2, several days 
after initial HFMD or herpangina, patients may 
develop CNS involvement, most commonly 
aseptic meningitis, encephalitis or acute fl accid 
paralysis (AFP). Aseptic meningitis is usually 
self-limiting. Encephalitis commonly involves 
the brainstem, cerebellum and spinal cord, 
and presents with myoclonic jerks, reduced 
consciousness, ataxia, and cranial nerve palsies. 
In a study of 1,548 severe cases, encephalitis was 
the most common manifestation of CNS disease.31 
AFP is the least common of the three main CNS 
complications. Children with AFP develop a 
poliomyelitis-like syndrome with acute onset of 
limb weakness with reduced refl exes.
Figure 4. Cutaneous vesicles (a, b) and ulcers on the tongue (c) in hand, foot and mouth disease.
7Cardiopulmonary involvement
Between several hours to two days following 
CNS involvement, stage 3 may occur, involving 
dysregulation of autonomic nervous system, and 
reduced myocardial function with progressive 
hypotension or pulmonary edema.55 The onset 
of this stage may lead to death within hours. 
Extensive infl ammation is always seen in the 
brainstem and spinal cord, but only occasionally 
in the lungs or myocardium. It is hypothesized 
that the cardiopulmonary failure is neurogenic in 
origin, due to EV-71 damage of the vasomotor 
centers in the medulla.36 
Long-term morbidity
Stage 4, the convalescence stage, is characterized 
by the long-term neurological sequelae of CNS 
involvement, which includes limb weakness, 
poorer cognitive ability, motor deficits and 
neurodevelopmental delay.13,56 Children recovered 
from EV-71 neurological illness may also have 
attention defi cit or hyperactivity problems in 
schools.57 
RISK FACTORS FOR SEVERE EV-71
Genetic variation of EV-71
One of the possible reasons that EV-71 continues 
to emerge as a more virulent virus is the presence 
of many subgenotypes within the virus. Ooi et al. 
(2007)58 showed that subgenotype C1 and B5 were 
more likely to cause CNS infection compared to 
subgenotype B4. In Taiwan, outbreaks with CNS 
involvement due to subgenotypes C2, B4 and B5 
were often preceded by shifts in the predominant 
circulating subgenotype of EV-71.59-60 
 Recombination in enteroviruses involves the 
breaking of viral nucleic acid before it is joined 
to another segment from a related virus. The 
resulting genetic variation may be benefi cial 
as it may allow immune escape, or it may 
alter viral virulence. The possible emergence 
of these different subgenotypes through inter-
typic recombination with other HEV-A has been 
shown.61 It is now known that at least genotype 
D and subgenotype B3 are recombinants of 
EV-71 with mosaic sequences of CV-A16.61-
62 Interestingly, experiments performed in 
suckling mice showed that the non-recombinant 
subgenotype B4 and recombinant subgenotypes 
B3 had different neurovirulence.63 
 Sequencing studies have shown that different 
clinical outcomes of EV-71 infection are associated 
with mutations at 5’UTR64-65, VP166, 2B64, 2C64, 
3A67, 3C64,68, 3D65, and 3’UTR68 regions. However, 
there have not yet been any consistent fi ndings 
of specifi c mutations that increase virulence that 
may be used in a clinically relevant manner. 
Co-infection
The possible role of co-infection of other 
infectious agents in increasing virulence cannot 
be excluded.  During the 1997 HFMD outbreak 
in Malaysia, adenovirus was also isolated11,34, 
while in 2000, echovirus 7 was isolated in severe 
cases.37 Nonetheless, it has also been recently 
reported that dual infection with other viruses 
(such as other enteroviruses or adenovirus) in 
Sarawak did not increase the risk of neurological 
complications.58 It is likely that co-infection of 
EV-71 with other HEV-A provides opportunity 
for recombination.
Host factors
Age
Based on our laboratory records of confi rmed 
HFMD cases from 1997-2007, the ages of children 
infected with EV-71 and CV-A16 were tabulated. 
Of the 145 confi rmed EV-71 cases from 1997-
2007, 9% were aged < 1, 65.5% were aged 1-3, 
18.6% were aged 4-6 and 5.5% were aged 7-12. 
Of the 32 confi rmed CV-A16 cases, 9.4% were 
aged <1, 71.9% were aged 1-3 and 18.8% were 
aged 4-6.  
 Many studies have showed that children below 
four years are the most susceptible to infection, 
and are summarized in Table 1. In Singapore, 
<1% of children of 6-23 months of age have 
neutralizing antibodies against EV-71, but by 
the age of fi ve, the rate was >50%.73  In Taiwan, 
seroprevalence of EV-71 in children aged 0.5-2 
years was only 4%, but in children above six 
years and adults, seroprevalence was 57-67%.54 
In Brazil, about 85% of patients aged 0-3 years 
had no neutralizing antibodies against EV-71, 
but by the age of 12-15, >70% had neutralizing 
antibodies.72 Another recent Taiwan study has 
shown that maternal neutralizing antibodies 
are present in about 50% of neonates, but are 
undetectable by 6 months of age.71  Taking together 
all these fi ndings, children between 6 months and 
3 years are at highest risk of acquiring EV-71 
infection due to lack of protective immunity. In 
addition, Chang et al. (2002)54 also showed that 
more severe and fatal EV-71 cases occurred in 
this age group. 
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Study population Country Prevalence of neutralizing References 
   antibodies
  Age group  Percentage 
    (%)
  
696 individuals aged 1- > 60 Germany 1-4  12 69
  5-9  49
436 healthy individuals aged 10 Germany 0-3   27.3 70
months-75   3-6  45.6
  6-10  56.4
  10-15  67.2
  > 20  75
459 pregnant women and their  Taiwan Adults (pregnant  63 71
neonates   mother)
  < 6 month  51
539 people (before the 1998 Taiwan < 0.6  36 54
 epidemic)  0.5-0.9  4
  1-1.9  4
  2-2.9  22
  3-5.9  36
  6-11.9  63
  12-19  66
238 patients aged <15 years with Brazil 0-3  14.8  72
symptoms of fever and exanthema  12-15  69.2 
856 children <12 years old Singapore 1-23 months  0.8 73
  2-5  12
  > 5  50
 
4619 donors Taiwan 0.5-3  4-26 74
  3-12  26-50
  Adults  >50
900 healthy children < 5  China < 5  32 75
years old 
Table 1: Seroprevalence studies for EV-71 from different countries
Cross-protection 
Cross-protection, or cross-neutralization, occurs 
when the host immunity induced by a virus also 
confers protective immunity against a different 
strain or closely-related virus. Generally, all 
enteroviruses are distinct serotypes but some 
enteroviruses such as CV-A3 and CV-A8, CV-A11 
and CV-A15 and CV-A13 and CV-A18 have been 
shown to cross-neutralize.4 However, with regards 
to the common HFMD viruses, previous CV-
A16 infection will not provide cross-protection 
to subsequent EV-71 infection and vice-versa. 
The issue of whether cross-protection occurs 
amongst the different subgenotypes of EV-71 
despite its high genetic variation is important, 
as it has implications for developing an effective 
vaccine. Kung et al. (2007)76 demonstrated a 
high degree of cross-neutralization among EV-
71 isolates of different subgenotypes of B and 
C. However Van Sanden et al. (2010)77 has 
shown that antisera derived from genotype B2 
poorly neutralized virus strains from genotype C. 
Further study is needed to resolve this question. 
9Antigenic variation in subgenotype B5 viruses 
did not fully protect the Taiwan population that 
had prior exposure to genotypes C and B4 and 
resulted in the Taiwan 2008 outbreak, the largest 
outbreak since 1998.60
 
Genetic factors
Genetic susceptibility to EV-71 infection 
has not been studied in detail. HLA-33 was 
strongly associated with EV-71 infection, while 
HLA-A2 was found more frequently in EV-71 
cardiopulmonary failure patients.78 As HLA-33 is 
an HLA type commonly seen in 17-35% of Asian 
populations, including Taiwan and Malaysia, and 
seen in <1% of white populations, it was suggested 
that this may explain why EV-71 outbreaks occur 
more frequently in Asian countries.78 Glucose 
6-phosphate defi ciency has also been shown to 
enhance EV-71 infection in vitro, but remains to 
be determined in human subjects.79   
CLINICAL AND LABORATORY 
BIOMARKERS
Reported clinical and laboratory markers of severe 
EV-71 infection are shown in Table 2. Increase of 
leukocyte counts in blood and CSF were noted in 
patients with pulmonary edema and encephalitis 
(Table 2). Generally, a poor cellular immunity 
response has been correlated with complicated 
EV-71 infection. Some studies have also reported 
the increase or decrease of cellular markers such 
as interleukins, however, most involved small 
number of patients with preliminary data and no 
conclusive fi ndings were noted. Cardiac troponin 
1 has been shown to be an early indicator of fatal 
EV-71 infection.87,89 Understanding these risk 
factors will aid in the management of HFMD 
patients by allowing identifi cation of those at risk 
of progression to severe neurological disease.    
LABORATORY DIAGNOSIS
During a HFMD outbreak, rapid diagnosis is 
important to identify the causative agent and 
implement proper control measures. The method 
of choice must be able to differentiate between 
EV-71 and CV-A16, because the latter usually 
causes uncomplicated HFMD. In addition, it is 
also imperative to closely monitor the emergence 
of new subgenotypes which may predispose to 
neurological complications and deaths.         
Choice of specimens
For diagnosis of EV-71, clinical specimens can 
include throat swabs, ulcer swabs, vesicle swabs/
fl uid, cerebrospinal fl uid, rectal swabs, stool and 
brain tissues. Blood is generally not useful, as 
enteroviruses may only be detected in blood 
at very early stages of infection.90 Generally, 
enteroviruses can be recovered from these sites 
during the fi rst few days of illness, and from rectal 
swabs and stool for many weeks afterwards.4 In 
our laboratory, EV-71 and CV-A16 were most 
frequently isolated from vesicle swabs (47/147, 
32%) followed by oral swabs (12/55, 21.8%), 
throat swabs (86/434, 19.8%), stool (34/180, 
18.9%), rectal swabs (89/519, 17.2%), ulcer swabs 
(7/47, 14.9%) and cerebrospinal fl uid (7/151, 
4.7%). These fi ndings were very similar to the 
evaluation performed in Sarawak and Taiwan.91-92 
As enterovirus infections are often asymptomatic, 
the isolation of enteroviruses from non-sterile sites 
such as throat and stool should be interpreted in 
the context of full clinical information, especially 
in the event of unusual or severe clinical disease. 
Isolation of enteroviruses from sterile sites such 
as CSF is always signifi cant, but may be diffi cult 
to achieve due to lower virus loads.
Laboratory methods
The gold standard of EV-71 diagnosis is virus 
isolation using mammalian tissue cultures and 
subsequent confi rmation with EV-71 specifi c 
monoclonal antibody. Mammalian cell cultures 
such as Vero (African green monkey kidney), 
human RD (rhabdomyosarcoma) cells, HeLa 
(cervical adenocarcinoma) cells and BGMK 
(buffalo green monkey kidney) support the 
growth of many enteroviruses.4 Cytopathic effects 
can be observed as early as day 2.  However, 
virus isolation is usually technically demanding, 
tedious, takes days to weeks, and has poor 
sensitivity. Detection of viral RNA by reverse-
transcriptase PCR (RT-PCR) is increasingly 
becoming the method of choice, as it is rapid and 
sensitive. Careful interpretation of PCR results is 
necessary for non-sterile sites, as residual RNA 
and live viruses can be shed in throat and stool 
for weeks.47 As genotyping is now considered an 
essential epidemiological tool, the right choice 
of genes for RT-PCR and genotyping is crucial 
since EV-71 frequently recombines and has high 
genetic variation. 5’UTR is frequently used for 
detection of enteroviruses while VP1 is used for 
genotyping. Recently, 3D has also been proposed 
for genotyping, as this gene is commonly involved 
in recombination in enteroviruses.42,93
 Commercial IgM capture ELISA is available 
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Table 2: Clinical risk factors and cellular markers of severe EV-71 infection
Study population Outcome Risk factors or cellular markers for outcome Reference 
725 children with EV-71 CNS disease Duration of fever ≥ 3 days  38
(Sarawak, Malaysia)  Peak temperature ≥ 38.5°C
  Lethargy 
78 children with EV71  Meningoencephalitis Younger children, boys 80
infection (Taiwan)  Increased total leukocyte count
  ↓ CD40-ligand expression in T cells
  G/G genotype at cytotoxic T lymphocyte 
  antigen-4 (CTLA-4) position 49 exon 1
31 children with brainstem Pulmonary edema Plasma:  81
encephalitis (Taiwan)  ↑ Interferon-γ induced protein 10 (IP-10)
  ↑ Monocyte chemoattractant protein 1 (MCP-1)
  ↑ Monokine induced by IFN-γ  (MIG)
  ↑ IL-8 
  CSF:
  ↑ Monokine induced by IFN-γ
57 children with brainstem  Pulmonary edema CSF: 82
encephalitis (Taiwan)  ↑ IL-1 β
  ↑ IFN-γ
30 children with CNS Pulmonary edema ↓  interferon-γ 83
disease (Taiwan)  ↓  IL-1β
  ↓  IL-6
  ↓ tumor necrosis factor -α
  ↓ cellular macrophage infl ammatory protein-1 α
73 EV-71 children with Pulmonary edema ↑ leukocytosis  84
brainstem encephalitis   ↑ thrombocytosis
(Taiwan)  ↑ plasma IL-10, IL-13, IFN-γ
  ↓ circulating lymphocyte CD4+ & CD8+ T cells, 
  natural killer cells
33 children with CNS  Pulmonary edema ↑ blood IL-6 85
infection (Taiwan)  ↑ TNF-α
  ↑ IL-1β
  ↑ white blood cell count
  ↑ blood glucose
154 children with  Pulmonary edema Hyperglycaemia 86
confi rmed EV-71 infection  Leucocytosis
  Limb weakness
  Tachycardia, tachypnoea & cyanosis 1-3 days 
  after onset
27 children with  Death ↑ troponin 1 87
cardiopulmonary failure   CSF white blood count > 100/μl
(Taiwan)  Initial diastolic pressure <  100 mm Hg
138 children with HFMD Death ↑ white blood cell count 88
(Singapore)  Absence of mouth ulcers
  Vomiting
21 children with CNS  Death ↑ Cardiac troponin I 89
infection (Taiwan) 
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for diagnosis of EV-71.94 This would be useful as 
most diagnostic laboratories have the capability to 
perform ELISA, but not virus isolation or PCR. 
Neutralization assays may be used to detect EV-
71 antibodies, but are laborious and used only in 
research settings. 
TREATMENT AND PREVENTION
Management
The majority of EV-71 cases are mild, do not 
require hospitalization, and can be treated 
symptomatically. However, the challenge, 
particularly during an outbreak situation with 
large numbers of infected children, is to identify 
the small numbers who are at risk of severe 
neurological disease. A prospective study in 
Sarawak identified and validated three risk 
factors for neurological involvement: fever 
for >3 days, peak temperature >38.5°C, and 
lethargy.38 The stage management approach by 
Chang et al. (2004)55 has improved the outcome 
of EV-71 infection in Taiwan. Management of 
EV-71 infection is mainly supportive, as there 
are still no effective anti-virals. Patients in stage 
2 who demonstrate CNS disease should be 
hospitalized, and closely monitored. Intravenous 
immunoglobulin (IVIG) has been used at this 
stage to reduce acute mortality in Taiwan and 
Malaysia.38,95 The mechanism of effect of IVIG 
is not known, but IVIG reduces plasma levels 
of cytokines which are raised in patients with 
EV-71-associated pulmonary edema.95 Patients 
in stage 3, with cardiopulmonary failure, require 
the necessary intensive care support, and may 
also benefi t from milrinone, which has inotropic 
and vasodilating properties to increase cardiac 
output.96 For Stage 4 patients, rehabilitation is 
required for limb weakness/atrophy and dysphagia, 
while those with diaphragm dysfunction, apnea 
or central hypoventilation may require long-term 
respiratory support.
Developments in anti-virals and vaccines 
EV-71 infection is often self-limiting and does not 
require any medication. However, in the case of 
neurological complications, anti-viral drugs would 
be benefi cial to improve the outcomes. Many 
new developments in anti-viral therapy are on-
going. Interferons, antibodies, capsid inhibitors, 
enviroxime-like compounds targeting the 3A 
and 3C protease inhibitors are potential anti-
picornaviral compounds.97 The capsid inhibitor 
pleconaril is one of the most promising enteroviral 
drugs, and is currently being tested in phase 2 
clinical trials for viral meningitis. However, its 
use has not been demonstrated for EV-71.  
 No anti-viral drug is currently available for 
EV-71. Nevertheless, there are numerous studies 
showing in vitro effects of many compounds 
against EV-71. Ribavirin, a nucleoside analogue 
has been shown to reduce viral load in cell 
culture and in animals.98 Lactoferrin has been 
shown to prevent entry of virus in the host cell 
by binding to EV-71 capsid VP1, protecting 
cells against EV-71 infection and mice against 
EV-71 lethal challenge.99-100 Other compounds 
reported with anti-EV-71 activity include the Raf-
1 inhibitor, GW5074101, capsid-binding, pyridyl 
imidazolidinones102-103 and the interferon inducer, 
aloe emodin.104  In addition, the therapeutic use 
of small-interfering RNA targeting the capsid and 
non-structural genes of EV-71 showed promising 
viral inhibition activity.105    
 A vaccine is highly desirable for EV-71. 
The conventional formalin-inactivated EV-71106 
and attenuated EV-71 strain107-108 are potential 
candidates for EV-71 vaccines. Other newer 
vaccines include oral vaccine with transgenic 
tomato109 and milk of transgenic mice100, virus-
like particles110, VP1 subunit vaccine106,111-112 and 
synthetic peptides targeting VP1.113
Prevention and control strategies for EV-71 
Hand-washing and environmental cleaning
The lack of proper hygiene and close contact 
between children facilitates faecal-oral spread. 
Simple handwashing with soap will remove 
the virus from hands. The virus is resistant to 
many disinfectants such as alcohol and phenolic 
disinfectants. The effi cacy of Virkon S, a peroxide-
based disinfectant has been tested and a minimum 
1% Virkon is suffi cient to kill the virus.51 Diluted 
chlorine (bleach) has also been recommended for 
cleaning surfaces and toys in nurseries during 
outbreaks. 
Public health control measures
Adequate surveillance systems should be in place 
to enable early detection and control of outbreaks. 
In Malaysia, the statutory notifi cation of HFMD 
has been in enforcement since 12 October 
2006, and HFMD guidelines were released by 
the Ministry of Health Malaysia in 2007.114 As 
previously shown, most of the transmission of 
EV-71 occurs in childcare settings or between 
household members.48,54,73 Under the guidelines, 
Neurology Asia March 2011
12
when two or more cases occur in the same 
childcare facility, the premise is advised to close 
for ten days from the date of onset of the last 
case, and must be thoroughly disinfected before 
reopening. Infected children should always have 
minimal contact with other people, particularly 
other children in the kindergarten or household. 
Public education, particularly during outbreaks, 
will also help to alert the public to adopt preventive 
measures. These include washing hands before 
preparing food, after going to the toilet, and 
after handling stool-soiled clothes or diapers, 
and covering the nose and mouth when coughing 
or sneezing.
CONCLUSION
EV-71 is an emerging virus with pandemic 
potential to cause severe neurological disease. 
Although large outbreaks are mainly seen in Asia, 
EV-71 disease is also increasingly found in Europe. 
In the absence of effective anti-virals, a vaccine 
offers the best strategy for control. However, many 
questions have not been addressed in vaccine 
development such as the target vaccination group 
and possibility of an universal EV-71 vaccine for 
all subgenotypes. In Malaysia, seroprevalence 
studies are needed to understand the baseline 
population immunity, the role of cross-protective 
antibodies across the different subgenotypes, 
and reasons for the cyclical outbreaks every 2-3 
years. Molecular surveillance at a national level 
will also help in understanding the viral genetic 
evolution that leads to recurring outbreaks, and 
contribute to development of vaccine and anti-
virals. Meanwhile, improvement of surveillance 
and proper risk communication to the public will 
help keep the highly contagious and potentially 
life-threatening infection at bay.
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